TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02497287
Drug: Sertraline (Oral Antidepressant)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
Study: NCT02497287
Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants \< 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants \>= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
Study: NCT03782376
Drug: Ustekinumab approximately 6 mg/kg (IV)
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
Study: NCT00129506
Drug: misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03019198
Drug: Tranexamic Acid Injectable Solution
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 15 mg per kilogram tranexamic acid
Study: NCT02780830
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
Study: NCT00671008
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00671008
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT03782376
Drug: Ustekinumab 90 mg (SC) Group 1
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
Study: NCT03782376
Drug: Ustekinumab 90 mg (SC) Group 2
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
Study: NCT02180438
Drug: Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks
Normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03556358
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
Study: NCT03556358
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
Study: NCT00903734
Drug: Erlotinib Hydrochloride (Tarceva)
Normalized name: erlotinib Oral Tablet [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of 150 mg daily by mouth.
Study: NCT04487080
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive amivantamab intravenously.
Study: NCT04487080
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive osimertinib capsules orally.
Study: NCT04487080
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive lazertinib tablets orally.
Study: NCT03559192
Drug: JNJ-67953964
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
Study: NCT03039192
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine solution 84 milligram (mg)
Study: NCT03387241
Drug: Fluticasone/ Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: See above
Study: NCT02493868
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
Study: NCT02493868
Drug: Duloxetine (Oral Antidepressant)
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study: NCT02493868
Drug: Escitalopram (Oral antidepressant)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
Study: NCT02493868
Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
Study: NCT02407236
Drug: Ustekinumab IV
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
Study: NCT02407236
Drug: Ustekinumab SC
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab will be administered as subcutaneously.
Study: NCT03596645
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
Study: NCT03596645
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
Study: NCT03818035
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
Study: NCT03387241
Drug: fluticasone/ salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: See above
Study: NCT03517722
Drug: Ustekinumab (approximately 6 mg/kg)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
Study: NCT03517722
Drug: Ustekinumab 90 mg
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 90 mg ustekinumab via SC route.
Study: NCT02215954
Drug: FE 999169
Normalized name: Fe
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
Study: NCT02521753
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intervention also includes weight reduction diet and exercise therapy
Study: NCT02714699
Drug: hyoscine butyl bromide
Normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
Study: NCT02638623
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L Lactated Ringer administered prior to primary knee or hip arthroplasty
Study: NCT00519259
Drug: Lobeline
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01155388
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental: Ferumoxytol
Study: NCT02953093
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm description
Study: NCT00533611
Drug: Comparator : niacin /Duration of Treatment : 1 Weeks
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01657266
Drug: Nevanac
Normalized name: Nevanac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-medication (before surgery) and maintenance treatment.
Study: NCT00756678
Drug: Lubricant Eye Drops (Optive™)
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop in both eyes as needed for 7 days'
Study: NCT00756678
Drug: Lubricating Eye Drops (blink® Tears)
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in both eyes as needed for 7 days
Study: NCT02322814
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
Study: NCT02322814
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Study: NCT02322814
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
Study: NCT02322814
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Study: NCT01164228
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01164228
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00005837
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03485677
Drug: Eliglustat GZ385660
Normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: Capsule, Liquid~Route of administration: Oral
Study: NCT03485677
Drug: Imiglucerase GZ437843
Normalized name: Imiglucerase
DrugBank: Imiglucerase (DB00053)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous
Study: NCT02929316
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion week 0, 2 and 6
Study: NCT03757234
Drug: Omadacycline
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: po tablets
Study: NCT03757234
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv solution/po tablets
Study: NCT03757234
Drug: Omadacycline
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv solution
Study: NCT00004390
Drug: methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004390
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004390
Drug: nortriptyline
Normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02104323
Drug: Endostatin
Normalized name: Endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
Study: NCT01199159
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
Study: NCT03253133
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 \* 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~\* Start level
Study: NCT03253133
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone
Study: NCT02422186
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants will start with first dose (Day 1 as 28 milligram \[mg\]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
Study: NCT02422186
Drug: Duloxetine (Oral Antidepressant)
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study: NCT02422186
Drug: Escitalopram (Oral Antidepressant)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
Study: NCT02422186
Drug: Sertraline (Oral Antidepressant)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
Study: NCT02422186
Drug: Venlafaxine Extended Release (XR) (New Antidepressant)
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
Study: NCT02005783
Drug: DBD
Normalized name: Dibenzoylmethane
DrugBank: Methane (DB15994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBD:one dose of medicine twice per day, orally
Study: NCT02005783
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin:90mg/m2, d1, q3w\*4
Study: NCT02005783
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel:75mg/m2, d1, q3w\*4
Study: NCT01527110
Drug: Intravenous (IV) zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
Study: NCT04101019
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
Study: NCT04101019
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
Study: NCT00001440
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00033189
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001529
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After medical clearance, volunteers will undergo outpatient mobilization with daily subcutaneous injections of filgrastim (G-CSF). The first dose will be administered at the NIH Clinical Center, with one-hour monitoring for immediate reactions. Volunteers may either return to NIH for daily injections or self-administer at home after training.
Study: NCT04055506
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 1
Study: NCT04055506
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg
Study: NCT01334762
Drug: Letrozole/IUI
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
Study: NCT00163215
Drug: Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
Study: NCT01026376
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
Study: NCT01026376
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
Study: NCT01793298
Drug: ASM-024
Normalized name: Asm-024 cation
DrugBank: Asm-024 cation (DB19385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending doses of ASM-024
Study: NCT04112277
Drug: Cumulative morphine consumption
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine equivalent \[mg\] 24 hours after the procedure
Study: NCT00002760
Drug: ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg PO tid for as long as treatment is effective
Study: NCT01871558
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 50 mg b.i.d
Study: NCT01871558
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin is to be kept unchanged
Study: NCT01871558
Drug: Basal Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no